Lenalidomide in 5q Minus Myelodysplastic Syndrome: How Long Is Enough?

Annals of Hematology - Germany
doi 10.1007/s00277-009-0775-x
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Unusual Clonal Evolution Involving 5q in a Case of Myelodysplastic Syndrome With Deletion 5q 31 Treated With Lenalidomide

Haematologica
Hematology
2008English

Antibiotics in Childhood Pneumonia: How Long Is Long Enough?

Pneumonia
2016English

Cryptic 5q Deletion in a Patient With Myelodysplastic Syndrome

British Journal of Haematology
Hematology
2017English

Elective ICP Monitoring: How Long Is Long Enough?

Fluids and Barriers of the CNS
MedicineMolecular NeuroscienceNeurologyDevelopmental NeuroscienceCellular
2015English

Lynch Syndrome and Long QT Syndrome – As if One Syndrome Is Not Already Enough

European Oncology and Haematology
OncologyHematology
2014English

Confidence: How Much Is Enough?

Constitutional Forum / Forum constitutionnel
2011English

Deletion 5q in Myelodysplastic Syndrome: A Paradigm for the Study of Hemizygous Deletions in Cancer

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2009English

Blood Consult: Treating Del(5q) Myelodysplastic Syndromes

Blood
BiochemistryImmunologyCell BiologyHematology
2012English

How Much Diversification Is Enough?

SSRN Electronic Journal
2003English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy